Literature DB >> 22778787

Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron.

Susan Lucak1.   

Abstract

Entities:  

Year:  2012        PMID： 22778787      PMCID： PMC3388526          DOI： 10.1177/1756283X12450934

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


× No keyword cloud information.
  23 in total

Review 1.  Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.

Authors:  Eric Shah; Sharon Kim; Kelly Chong; Anthony Lembo; Mark Pimentel
Journal:  Am J Med       Date:  2012-04       Impact factor: 4.965

2.  Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.

Authors:  M E Watson; L Lacey; S Kong; A R Northcutt; D McSorley; B Hahn; A W Mangel
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

3.  A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme.

Authors:  D Miller; L Bennett; K Hollis; P Tennis; S Cook; E Andrews
Journal:  Aliment Pharmacol Ther       Date:  2006-09-01       Impact factor: 8.171

Review 4.  Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?

Authors:  Georg Stacher
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2007-10       Impact factor: 3.869

5.  Diseases and drugs that increase risk of acute large bowel ischemia.

Authors:  George F Longstreth; Janis F Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2009-09-16       Impact factor: 11.382

6.  International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit.

Authors:  Douglas A Drossman; Carolyn Blank Morris; Susan Schneck; Yuming J B Hu; Nancy J Norton; William F Norton; Stephan R Weinland; Christine Dalton; Jane Leserman; Shrikant I Bangdiwala
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

7.  Assessment of potential risk factors associated with ischaemic colitis.

Authors:  L Chang; K H Kahler; C Sarawate; R Quimbo; J Kralstein
Journal:  Neurogastroenterol Motil       Date:  2007-09-27       Impact factor: 3.598

8.  Epidemiology, clinical features, high-risk factors, and outcome of acute large bowel ischemia.

Authors:  George F Longstreth; Janis F Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2009-06-23       Impact factor: 11.382

9.  Irritable bowel syndrome is more frequent in patients hospitalized for ischaemic colitis: results of a case-control study.

Authors:  S Hervé; L Beaugerie; Y Bouhnik; G Savoye; J-F Colombel; F Dyard; I Hourmand-Ollivier; T Dao; M Vial; E Lerebours
Journal:  Neurogastroenterol Motil       Date:  2009-05-21       Impact factor: 3.598

Review 10.  Systematic review: the epidemiology of ischaemic colitis.

Authors:  P D R Higgins; K J Davis; L Laine
Journal:  Aliment Pharmacol Ther       Date:  2004-04-01       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.